US Patent 10947319 Bispecific antigen-binding constructs targeting HER2
Patent 10947319 was granted and assigned to Zymeworks Inc. on March, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+420 characters)
Article
Patent abstract
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 7 Apr, 2023
Golden AI
Infobox
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
109473190
Date of Patent
March 16, 2021
0Patent Application Number
150361760
Date Filed
November 27, 2014
0Official Website
Patent Citations Received
Patent Primary Examiner
Edits on 28 Oct, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 25 Sep, 2022
Golden AI
Infobox
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10947319 Bispecific antigen-binding constructs targeting HER2
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10947319
Date of patent
March 16, 2021
Patent application number
15036176
Date Filed
November 27, 2014
Patent primary examiner
Find more entities like US Patent 10947319 Bispecific antigen-binding constructs targeting HER2
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
